查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1820348

奈米医学市场规模、份额、趋势及预测（按奈米分子类型、产品、应用和地区），2025 年至 2033 年

Nanomedicine Market Size, Share, Trends and Forecast by Nanomolecule Type, Product, Application, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球奈米医药市场规模为 2,940.4 亿美元。展望未来， IMARC Group估计，到 2033 年，市场规模将达到 7,791.9 亿美元，2025-2033 年期间的复合年增长率为 10.86%。北美目前占据市场主导地位，2024 年将占据 49.9% 的显着市场。标靶药物传递需求的不断增长、奈米技术的进步、慢性病患病率的上升、诊断和治疗应用的不断扩大，以及为创造更有效、个性化和微创的医疗方法而不断增加的研发投资，是推动奈米医药市场份额增长的一些主要因素。

奈米医学市场的发展主要得益于奈米技术的进步及其与医疗保健应用的日益融合。标靶药物输送系统的发展提升了医疗效果，并减少了主要见于癌症、心臟病和脑部疾病的副作用。随着慢性病患者人数的不断增加，寻求更优的治疗方法变得愈发重要。此外，奈米技术在诊断、再生医学和影像领域的应用日益广泛，有助于提高疾病的早期发现率和个人化治疗的效果。市场经济成长得益于公共和私营部门在奈米医学研发 (R&D) 领域日益活跃的活力。由于监管机构的广泛支持和新药研究的发展，奈米医学正成为全球未来医疗解决方案的重要组成部分。

美国奈米医药市场的成长得益于奈米技术的进步，奈米技术促进了靶向药物传输系统的开发、提高了治疗效果并减少了副作用。心血管疾病和癌症等慢性疾病的发生率不断上升，对创新治疗方案的需求也随之增加。根据美国国立卫生研究院 (NIH) 的数据，到 2025 年，美国可能会新增约 2,041,910 例癌症病例，其中 618,120 人死于癌症。来自私营和公共部门的大量投资支持了广泛的研发 (R&D) 活动，促进了该领域的创新。美国食品药物管理局 (FDA) 提供了一个良好的监管环境，促进了奈米医药产品的批准和商业化。此外，对个人化医疗和早期疾病检测的日益重视扩大了奈米技术在诊断和治疗中的应用，进一步推动了市场成长。

奈米医药市场趋势

奈米科技的进步

奈米技术的持续创新是奈米医药市场扩张的主要动力。研究人员开发出了奈米级材料和设备，可实现精准药物传输、标靶治疗和增强成像技术。这些突破透过最大限度地减少副作用和提高治疗准确性来改善治疗效果。奈米颗粒、脂质体、树枝状聚合物和奈米机器人正被设计用于从癌症治疗到组织修復等各种应用。诊断工具的微型化也使即时监测和早期疾病检测更加有效。随着奈米技术的不断发展，它为复杂疾病的管理开闢了新的可能性，为医疗专业人员提供更精细、侵入性更小的工具。根据奈米医药市场预测，这些创新对于整个医疗产业日益普及和投资奈米医药至关重要。例如，2025年5月，专注于奈米医药的合约研究机构Nanoworx BV为学术界和商界的合作伙伴提供了广泛的服务组合。 Nanoworx 是一家位于荷兰埃因霍温的公司，利用尖端机械和丰富的经验，推动基于奈米粒子的解决方案的设计、开发和可扩展性。

加大研发投入

来自公共和私营部门的大量投资正在推动奈米医学的进步。政府、研究机构和製药公司正在投入大量资金，用于开发基于奈米技术的新型疗法、诊断方法和药物输送系统。这些投资加速了奈米医学的创新，并促进了其从实验室到临床应用的转变。大学、生物技术公司和医疗保健提供者之间的合作正在促进跨学科研究，从而带来新的发现并加速产品的商业化。此外，创投对奈米技术新创企业的支持有助于将早期创新成果推向市场。这种强劲的融资环境使得人们能够持续探索基于奈米的解决方案，以满足尚未满足的医疗需求，使奈米医学成为全球医疗保健领域的关键成长领域和技术领先地位。例如，2024年4月，CBC株式会社与Nanoform芬兰有限公司（「Nanoform」）宣布达成策略合作，CBC将利用其在日本製药业的丰富知识，为Nanoform先进的奈米医学工程技术寻找发展机会。事实证明，奈米药物，无论是新型治疗方法还是现有产品的改良版本，都可以透过减少剂量和药丸负荷以及解决创新者对药物生物利用度的担忧来提高患者的接受度。

有利的监管支持和临床进展

支持性的监管框架和持续的临床进展正在创造积极的奈米医药市场前景。美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等监管机构已创建评估和批准基于奈米技术的产品的途径，增强了开发者和消费者的信心。简化的审查流程、指导文件和清晰的监管规定有助于加速产品开发和市场准入。同时，越来越多基于奈米医药疗法的成功临床试验验证了其安全性和有效性，为公共卫生和投资者利益注入了动力。监管机构还支持上市后监测和品质控制标准，以确保患者的持续安全。监管支援和临床验证的结合使得奈米医药产品能够得到更广泛的应用，增强信任，并促进其更广泛地融入医疗保健系统。例如，2024年9月，芝加哥大学医学综合癌症中心的研究人员研发出一种奈米药物，可以有效破坏小鼠体内的癌细胞，并提高化疗药物在肿瘤组织中的渗透和累积。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球奈米医学市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场细分：依奈米分子类型

  • 奈米粒子
    • 主要类型
      • 金属和金属氧化物奈米粒子
      • 脂质体
      • 聚合物和聚合物药物偶联物
      • 水凝胶奈米颗粒
      • 树枝状聚合物
      • 无机奈米粒子
  • 奈米壳
  • 奈米管
  • 奈米装置

第七章：市场区隔：依产品

  • 疗法
  • 再生医学
  • 体外诊断
  • 体内诊断
  • 疫苗

第 8 章：市场区隔：按应用

  • 临床肿瘤学
  • 传染病
  • 临床心臟病学
  • 骨科
  • 其他的

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 10 章：SWOT 分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Arrowhead Pharmaceuticals Inc.
    • General Electric Company
    • Luminex Corporation
    • Merck & Co. Inc.
    • Nanobiotix
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Starpharma Holdings Limited
Product Code: SR112025A4052

The global nanomedicine market size was valued at USD 294.04 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 779.19 Billion by 2033, exhibiting a CAGR of 10.86% during 2025-2033. North America currently dominates the market, holding a significant market share of 49.9% in 2024. The rising demand for targeted drug delivery, advancements in nanotechnology, increased prevalence of chronic diseases, expanding applications in diagnostics and therapeutics, and growing investments in research and development to create more effective, personalized, and minimally invasive medical treatments are some of the major factors fueling the nanomedicine market share.

The market for nanomedicine is primarily fueled by advancements in nanotechnology and its growing integration into healthcare applications. The development of targeted drug delivery systems has increased the benefits of medical treatments and decreased the side effects mainly seen in cancers and heart and brain conditions. With the growing number of people having chronic diseases, the search for better treatments becomes more important. In addition, the use of nanotechnology for diagnostics, regenerative medicine and imaging is increasing, improving both early finding of diseases and tailored care. The economic growth of the market is supported by greater activity from both public and private sectors in nanomedicine research and development (R&D). Because of general support from regulators and new drug studies, nanomedicine is becoming a crucial aspect of future medical solutions globally.

The nanomedicine market growth in the United States is propelled by advancements in nanotechnology, which have facilitated the development of targeted drug delivery systems and enhanced treatment efficacy and reducing side effects. The rising prevalence of chronic diseases, like cardiovascular conditions and cancer, has amplified the demand for innovative therapeutic solutions. According to the NIH, in 2025, approximately 2,041,910 new cancer cases are likely to be identified in the United States, with 618,120 individuals succumbing to the illness. Substantial investments from private and public sectors support extensive research and development (R&D) activities, fostering innovation in the field. The U.S. Food and Drug Administration (FDA) provides a favorable regulatory environment that facilitates the approval and commercialization of nanomedicine products. Additionally, the growing emphasis on personalized medicine and early disease detection has expanded the applications of nanotechnology in diagnostics and therapeutics, further driving market growth.

Nanomedicine Market Trends

Advancements in Nanotechnology

Ongoing innovations in nanotechnology are a primary force behind the expansion of the nanomedicine market. Researchers have developed nanoscale materials and devices that enable precise drug delivery, targeted therapy, and enhanced imaging techniques. These breakthroughs improve therapeutic outcomes by minimizing side effects and increasing treatment accuracy. Nanoparticles, liposomes, dendrimers, and nanorobots are being engineered for applications ranging from cancer treatment to tissue repair. The miniaturization of diagnostic tools has also made real-time monitoring and early disease detection more effective. As nanotechnology continues to evolve, it opens new possibilities for complex disease management, providing healthcare professionals with more refined, less invasive tools. According to the nanomedicine market forecast, these innovations are central to the increasing adoption and investment in nanomedicine across the healthcare industry. For instance, in May 2025, Nanoworx B.V., a nanomedicine-focused contract research organization, provided its extensive service portfolio for partners in academia and business. Nanoworx, a company established in Eindhoven, the Netherlands, advances the design, development, and scalability of nanoparticle-based solutions by utilizing cutting-edge machinery and extensive experience.

Growing Investments in Research and Development

Significant investments from both public and private sectors are fueling advancements in nanomedicine. Governments, research institutions, and pharmaceutical companies are allocating substantial funding to develop novel nanotechnology-based therapies, diagnostics, and drug delivery systems. These investments accelerate innovation and the transition of nanomedicine from the lab to clinical applications. Collaborations among universities, biotech firms, and healthcare providers are promoting interdisciplinary research, leading to new discoveries and faster commercialization of products. Moreover, venture capital support for nanotech startups is helping to bring early-stage innovations to market. This robust funding environment enables continued exploration of nano-based solutions for unmet medical needs, positioning nanomedicine as a key area of growth and technological leadership within the global healthcare landscape. For instance, in April 2024, CBC Co., Ltd. and Nanoform Finland Plc ("Nanoform") announced a strategic cooperation in which CBC would use its vast knowledge of the Japanese pharmaceutical sector to find opportunities for Nanoform's state-of-the-art nanomedicine engineering technology. It has been demonstrated that nano-formed medications, whether they are novel treatments or reformulated versions of existing goods, can increase patient acceptance by reducing dose size and pill load and resolving innovators' concerns about drug bioavailability.

Favorable Regulatory Support and Clinical Advancements

Supportive regulatory frameworks and ongoing clinical advancements are creating a positive nanomedicine market outlook. Regulatory bodies such as the U.S. FDA and EMA have created pathways to evaluate and approve nanotechnology-based products, fostering confidence among developers and consumers. Streamlined review processes, guidance documents, and regulatory clarity help accelerate product development and market entry. In parallel, increasing numbers of successful clinical trials for nanomedicine-based therapies validate their safety and effectiveness, building momentum in both public health and investor interest. Regulatory agencies also support post-market surveillance and quality control standards, ensuring continued patient safety. This combination of regulatory support and clinical validation enables wider adoption of nanomedicine products, reinforcing trust and facilitating broader integration into healthcare systems. For instance, in September 2024, researchers at the University of Chicago Medicine Comprehensive Cancer Center shaped a nanomedicine that efficiently destroys cancer cells in mice and improves the penetration and buildup of chemotherapy medications in tumor tissues.

Nanomedicine Industry Segmentation:

Analysis by Nanomolecule Type:

  • Nanoparticles
    • Metal and Metal Oxide Nanoparticles
    • Liposomes
    • Polymers and Polymer Drug Conjugates
    • Hydrogel Nanoparticles
    • Dendrimers
    • Inorganic Nanoparticles
  • Nanoshells
  • Nanotubes
  • Nanodevices

Nanoparticles stand as the largest nanomolecule type in 2024, holding 76.7% of the market due to their exceptional versatility, precision, and effectiveness in delivering therapeutic agents. Their small size allows them to penetrate biological barriers and accumulate in target tissues, particularly tumors, through enhanced permeability and retention (EPR) effects. This enables targeted drug delivery, reducing toxicity to healthy cells and improving treatment outcomes. Additionally, nanoparticles can be engineered with surface modifications to enhance the solubility, stability, and bioavailability of drugs. Their applications span a wide range of medical fields, including oncology, cardiology, infectious diseases, and neurology. With growing investments in research, continuous innovation, and increasing adoption in clinical trials, nanoparticles remain the preferred platform for developing next-generation nanomedicines across diagnostics, therapeutics, and regenerative medicine.

Analysis by Product:

  • Therapeutics
  • Regenerative Medicine
  • In-Vitro Diagnostics
  • In-Vivo Diagnostics
  • Vaccines

Therapeutics leads the market with 34.7% of market share in 2024 due to their transformative role in enhancing treatment efficacy, reducing side effects, and enabling targeted drug delivery. Nanotherapeutics offer precise delivery of active pharmaceutical ingredients to specific cells or tissues, which is especially valuable in treating complex diseases such as cardiovascular disorders, cancer, and neurological conditions. This precision reduces damage to healthy cells and improves patient outcomes. Additionally, nanomedicine enables controlled and sustained drug release, increasing bioavailability and patient compliance. As chronic diseases become more prevalent globally, the demand for advanced therapeutic solutions continues to rise. Coupled with strong investment in research and development (R&D) and numerous ongoing clinical trials, the therapeutic segment remains the most commercially mature and widely adopted application within the nanomedicine market.

Analysis by Application:

  • Clinical Oncology
  • Infectious Diseases
  • Clinical Cardiology
  • Orthopedics
  • Others

Clinical oncology leads the market with 32.5% of market share in 2024 due to the high demand for more effective and targeted cancer treatments. Nanomedicine enables the delivery of chemotherapeutic agents directly to tumor cells while minimizing exposure to healthy tissues, significantly reducing side effects and improving treatment outcomes. This precision is crucial in oncology, where conventional therapies often cause severe systemic toxicity. Additionally, nanocarriers improve drug solubility and bioavailability, and can bypass drug resistance mechanisms in tumors. The increasing global cancer burden has driven extensive research, development, and clinical adoption of nanotechnology-based therapies. With numerous nanomedicine oncology products already approved or in advanced clinical trials, this application continues to lead the market, supported by strong investment and regulatory interest in cancer innovation.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share of 49.9%. The nanomedicine market demand in North America is influenced by a combination of advanced healthcare infrastructure, strong research capabilities, and significant investment in nanotechnology. The region benefits from a high prevalence of chronic diseases, like cardiovascular disorders and cancer, which increases demand for targeted and effective treatment options. Robust support from government agencies, including funding for nanomedicine research through institutions like the NIH, accelerates innovation and clinical translation. Additionally, the presence of leading pharmaceutical and biotechnology companies fosters the development and commercialization of nanomedicine products. Regulatory agencies like the FDA provide structured pathways for approval, encouraging product adoption. With growing awareness of precision medicine and early diagnosis, North America remains a global leader in nanomedicine research, development, and market share growth.

Key Regional Takeaways:

United States Nanomedicine Market Analysis

In 2024, the United States accounted for 92.60% of the nanomedicine market in North America. The United States nanomedicine market is mainly fueled by the increasing prevalence of chronic conditions, such as cancer and neurological disorders. According to the NCI, an estimated 2,041,910 new cancer cases and 618,120 cancer deaths are expected in the U.S. in 2025. The cancer incidence rate is 445.8 per 100,000 people annually (2018-2022), while the mortality rate is 145.4 per 100,000 people annually (2019-2023). By this, growing federal and private investment in nanotechnology R&D is accelerating innovation and commercialization in the sector. Similarly, the increasing presence of leading research institutions and academic partnerships is enabling efficient technology transfer and product development. Furthermore, continual regulatory advancements, including the FDA's adaptive pathways for nanomedicines, are facilitating smoother clinical translation and impelling the market. Additionally, expanding applications in regenerative medicine, including stem cell nanocarriers and scaffold integration, are widening the market scope. The rising demand for precision therapies, encouraging the development of nanoparticle-based diagnostics and treatments, is strengthening the market demand. Likewise, strong industry participation in targeted delivery platforms is enhancing therapeutic efficacy and market appeal. Moreover, strategic collaborations and licensing deals are further accelerating innovation and market penetration.

Europe Nanomedicine Market Analysis

The market in Europe is experiencing growth due to rising public healthcare investment and strategic funding initiatives under Horizon Europe. According to Eurostat, in 2022, 51.3% of existing healthcare spending in the EU was funded through mandatory schemes and savings accounts, 30.0% by governmental programs, while the final 18.7% was provided by other funding sources. In line with this, expanding adoption of nanosensors in early disease detection technologies, supporting diagnostic accuracy and speed, is propelling the market growth. The region's ongoing shift toward personalized healthcare is encouraging the uptake of targeted nanotherapies, especially in oncology and rare diseases. Furthermore, the well-regulated clinical trial environment across Europe is enabling efficient testing and approval of novel nanomedicine products. Furthermore, continual technological advances in nanoparticle design are allowing more controlled drug release, improving patient outcomes, and treatment adherence. Similarly, increasing collaboration between universities, biotech startups, and pharma firms is accelerating market expansion. The growing focus on non-invasive delivery platforms such as intranasal and transdermal nanoformulations is broadening market reach. Moreover, strong emphasis on research-driven innovation, solidifying Europe's leadership in nanomedicine development, is creating lucrative market opportunities.

Asia Pacific Nanomedicine Market Analysis

The Asia Pacific nanomedicine market is majorly driven by rising healthcare expenditure and the increasing burden of chronic diseases across rapidly developing economies. In addition to this, government-supported nanotechnology programs in China, Japan, and South Korea are strengthening regional research infrastructure and translational capabilities, which is impelling the market. Similarly, the growing role of contract research and manufacturing organizations, enabling efficient and cost-effective development of nanomedicine solutions, is fostering market expansion. Furthermore, the rapid integration of artificial intelligence with nanotechnology for targeted drug delivery is enhancing treatment accuracy and personalization, thereby stimulating market appeal. Apart from this, the rise in medical tourism across countries such as India, Thailand, and Malaysia, generating demand for advanced, minimally invasive therapies, is providing an impetus to the market. According to data shared in the Parliament, foreign medical visitors to India reached nearly 6.6 lakh in 2023, reflecting steady post-pandemic growth.

Latin America Nanomedicine Market Analysis

In Latin America, the market is advancing due to rising government-backed initiatives focused on biotechnology and nanoscience through national development agendas. Similarly, the growth of public-private research collaborations, enhancing regional capacity for innovation and infrastructure development, is propelling the market growth. Furthermore, the increasing burden of infectious diseases is prompting healthcare systems to adopt nano-enabled diagnostics and drug delivery platforms for greater therapeutic precision. Moreover, the expansion of clinical trial networks in countries like Brazil and Argentina, supported by regulatory reforms and competitive operating costs, is attracting global investments in nanotechnology-driven healthcare solutions. According to the Regulatory Affairs Professionals Society (RAPS), as of April 2024, around 10,000 clinical studies were recorded in Brazil, positioning it as the frontrunner in clinical trials within Latin America, with Mexico trailing at approximately 5,000 and Argentina at 4,000.

Middle East and Africa Nanomedicine Market Analysis

The market in the Middle East and Africa is advancing with increased public investment in healthcare innovation, particularly through national transformation plans in countries like Saudi Arabia and the UAE. Furthermore, the rising burden of non-communicable diseases, such as cancer and diabetes, is encouraging the adoption of nanomedicine for targeted treatment and precision diagnostics. As per NCBI, the GCC countries saw an expected 42,475 new cases of cancer and 19,895 deaths in 2020; the age-standardized incidence and mortality rates were 96.5 and 52.3 per 100,000, respectively. Additionally, growing collaboration with global research institutions is enhancing regional access to cutting-edge nanotechnology and accelerating product development. Besides this, expanding interest in personalized healthcare solutions across urban medical centers supporting the integration of nanotherapeutics into mainstream treatment pathways is impacting market dynamics.

Competitive Landscape:

The nanomedicine market is highly competitive, characterized by a mix of established pharmaceutical companies, innovative biotech startups, and academic research institutions. Key players such as Pfizer, Johnson & Johnson, Abbott Laboratories, and Merck & Co. are actively investing in nanotechnology to enhance drug delivery systems and develop advanced therapies. Emerging companies like Nanoform, Nanobiotix, and Selecta Biosciences are gaining traction with specialized platforms for targeted treatment. Collaborations, licensing agreements, and strategic partnerships are common as firms seek to expand their technological capabilities and market reach. Continuous innovation, strong R&D pipelines, and a focus on oncology and chronic disease treatment are central to competitive positioning. Regulatory approvals and clinical trial progress play critical roles in shaping market leadership and driving commercial success.

The report provides a comprehensive analysis of the competitive landscape in the nanomedicine market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Arrowhead Pharmaceuticals Inc.
  • General Electric Company
  • Luminex Corporation
  • Merck & Co. Inc.
  • Nanobiotix
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Starpharma Holdings Limited

Key Questions Answered in This Report

  • 1.How big is the nanomedicine market?
  • 2.What is the future outlook of nanomedicine market?
  • 3.What are the key factors driving the nanomedicine market?
  • 4.Which region accounts for the largest nanomedicine market share?
  • 5.Which are the leading companies in the global nanomedicine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Nanomedicine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Nanomolecule Type

  • 6.1 Nanoparticles
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Metal and Metal Oxide Nanoparticles
      • 6.1.2.2 Liposomes
      • 6.1.2.3 Polymers and Polymer Drug Conjugates
      • 6.1.2.4 Hydrogel Nanoparticles
      • 6.1.2.5 Dendrimers
      • 6.1.2.6 Inorganic Nanoparticles
    • 6.1.3 Market Forecast
  • 6.2 Nanoshells
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Nanotubes
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Nanodevices
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Therapeutics
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Regenerative Medicine
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 In-Vitro Diagnostics
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 In-Vivo Diagnostics
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Vaccines
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Clinical Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Infectious Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Clinical Cardiology
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Orthopedics
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Arrowhead Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 General Electric Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Luminex Corporation
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Merck & Co. Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Nanobiotix
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Novartis AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi SA
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Starpharma Holdings Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials

List of Figures

  • Figure 1: Global: Nanomedicine Market: Major Drivers and Challenges
  • Figure 2: Global: Nanomedicine Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Nanomedicine Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Nanomedicine Market: Breakup by Nanomolecule Type (in %), 2024
  • Figure 5: Global: Nanomedicine Market: Breakup by Product (in %), 2024
  • Figure 6: Global: Nanomedicine Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Nanomedicine Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Nanomedicine (Nanoparticles) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Nanomedicine (Nanoparticles) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Nanomedicine (Nanoshells) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Nanomedicine (Nanoshells) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Nanomedicine (Nanotubes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Nanomedicine (Nanotubes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Nanomedicine (Nanodevices) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Nanomedicine (Nanodevices) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Nanomedicine (Therapeutics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Nanomedicine (Therapeutics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Nanomedicine (Regenerative Medicine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Nanomedicine (Regenerative Medicine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Nanomedicine (In-Vitro Diagnostics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Nanomedicine (In-Vitro Diagnostics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Nanomedicine (In-Vivo Diagnostics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Nanomedicine (In-Vivo Diagnostics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Nanomedicine (Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Nanomedicine (Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Nanomedicine (Clinical Oncology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Nanomedicine (Clinical Oncology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Nanomedicine (Infectious Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Nanomedicine (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Nanomedicine (Clinical Cardiology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Nanomedicine (Clinical Cardiology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Nanomedicine (Orthopedics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Nanomedicine (Orthopedics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Nanomedicine (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Nanomedicine (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: North America: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: North America: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: United States: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: United States: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Canada: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Canada: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Asia-Pacific: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Asia-Pacific: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: China: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: China: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Japan: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Japan: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: India: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: India: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: South Korea: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: South Korea: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Australia: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Australia: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Indonesia: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Indonesia: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Others: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Others: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Europe: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Europe: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Germany: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Germany: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: France: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: France: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: United Kingdom: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: United Kingdom: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Italy: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Italy: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Spain: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Spain: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Russia: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Russia: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Latin America: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Latin America: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Brazil: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Brazil: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Mexico: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Mexico: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Others: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Others: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Middle East and Africa: Nanomedicine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Middle East and Africa: Nanomedicine Market: Breakup by Country (in %), 2024
  • Figure 84: Middle East and Africa: Nanomedicine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Global: Nanomedicine Industry: SWOT Analysis
  • Figure 86: Global: Nanomedicine Industry: Value Chain Analysis
  • Figure 87: Global: Nanomedicine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Nanomedicine Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Nanomedicine Market Forecast: Breakup by Nanomolecule Type (in Million USD), 2025-2033
  • Table 3: Global: Nanomedicine Market Forecast: Breakup by Product (in Million USD), 2025-2033
  • Table 4: Global: Nanomedicine Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Nanomedicine Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Nanomedicine Market: Competitive Structure
  • Table 7: Global: Nanomedicine Market: Key Players